Rani Therapeutics has developed a novel approach for the oral delivery of large drug molecules, which to date can only be delivered through injections. The approach and technology for Rani Therapeutics was developed at InCube Labs, a multi-disciplinary life sciences R&D lab focused on developing breakthrough medical innovations.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 08/28/13 | undisclosed | Series B |
InCube Ventures VentureHealth | undisclosed |
| 05/27/15 | undisclosed | Series C |
InCube Ventures Novartis Venture Funds VentureHealth | undisclosed |
| 09/13/17 | $39,000,000 | Series D |
AstraZeneca Bossa Nova Investments Buttonwood Cathay Ventures Crystal Horizon Investments Novartis Venture Funds Pacific Venture Opportunity Fund Pinemount Investments | undisclosed |
| 02/09/18 | $53,000,000 |
AstraZeneca Bossa Ventures Cathay Ventures GeneScience Pharmaceuticals Novartis Ping An Ventures Virtus Ventures | undisclosed | |
| 12/10/20 | $69,000,000 | Series E |
